Nucleic acids encoding mosaic conserved region HIV immunogenic polypeptides
Disclosed herein are mosaic conserved region HIV polypeptides and immunogenic polypeptides including one or more of the mosaic conserved region polypeptides. In some embodiments, the immunogenic polypeptides are included in an immunogenic composition, such as a polyvalent immunogenic composition. Also disclosed herein are methods for treating or inhibiting HIV in a subject including administering one or more of the disclosed immunogenic polypeptides or compositions to a subject having or at risk of HIV infection. In some embodiments, the methods include inducing an immune response in a subject comprising administering to the subject at least one of the disclosed immunogenic polypeptides or a nucleic acid encoding at least one of the immunogenic polypeptides.
1. An isolated nucleic acid encoding:
an immunogenic fusion polypeptide consisting of two or more of the amino acid sequences of SEQ ID NOs: 1-18, or
an immunogenic fusion polypeptide consisting of two or more amino acid sequences having at least 95% identity to the amino acid sequence of any one of SEQ ID NOs: 1-18.
2. The isolated nucleic acid of claim 1 , wherein the immunogenic fusion polypeptide consists of each of SEQ ID NOs: 2, 3, 6, 7, 8, and 17, or amino acid sequences having at least 95% identity to each of SEQ ID NOs: 2, 3, 6, 7, 8, and 17.
3. The isolated nucleic acid of claim 1 , wherein the immunogenic fusion polypeptide consists of each of SEQ ID NOs: 10, 11, 14, 15, 16, and 18, or amino acid sequences having at least 95% identity to each of SEQ ID NOs: 10, 11, 14, 15, 16, and 18.
4. The isolated nucleic acid of claim 1 , wherein the immunogenic fusion polypeptide consists of two or more of SEQ ID NOs: 1-8 and 17, or amino acid sequences having at least 95% identity to SEQ ID NOs: 1-8 and 17.
5. The isolated nucleic acid of claim 1 , wherein the immunogenic fusion polypeptide consists of each of SEQ ID NOs: 1-8, or amino acid sequences having at least 95% identity to each of SEQ ID NOs: 1-8.
6. The isolated nucleic acid of claim 1 , wherein the immunogenic fusion polypeptide consists of each of SEQ ID NOs: 1, 2, 3, 6, 7, 8, and 17, or amino acid sequences having at least 95% identity to each of SEQ ID NOs: 1, 2, 3, 6, 7, 8, and 17.
7. The isolated nucleic acid of claim 1 , wherein the immunogenic fusion polypeptide consists of two or more of SEQ ID NOs: 9-16 and 18, or amino acid sequences having at least 95% identity to SEQ ID NOs: 9-16 and 18.
8. The isolated nucleic acid of claim 1 , wherein the immunogenic fusion polypeptide consists of each of SEQ ID NOs: 9-16, or amino acid sequences having at least 95% identity to each of SEQ ID NOs: 9-16.
9. The isolated nucleic acid of claim 1 , wherein the immunogenic fusion polypeptide consists of each of SEQ ID NOs: 9, 10, 11, 14, 15, 16, and 18, or amino acid sequences having at least 95% identity to each of SEQ ID NOs: 9, 10, 11, 14, 15, 16, and 18.
10. The isolated nucleic acid of claim 1 , operably linked to a promoter.
11. The isolated nucleic acid of claim 1 , operably linked to a nucleic acid encoding a leader peptide.
12. A vector comprising the isolated nucleic acid of claim 10 .
13. A pharmaceutical composition comprising:
one or more of the isolated nucleic acids of claim 1 ; and
a pharmaceutically acceptable carrier.
14. The pharmaceutical composition of claim 13 , further comprising one or more of an adjuvant, a detergent, a micelle-forming agent, and an oil.
15. A method for eliciting an immune response to human immunodeficiency virus (HIV) in a subject, comprising administering to the subject an effective amount of one or more of the isolated nucleic acid of claim 1 , thereby eliciting an immune response to HIV in the subject.
16. The method of claim 15 , wherein the one or more isolated nucleic acids encode two or more of:
the immunogenic fusion polypeptide consisting of each of SEQ ID NOs: 1-8;
the immunogenic fusion polypeptide consisting of each of SEQ ID NOs: 1, 2, 3, 6, 7, 8, and 17;
the immunogenic fusion polypeptide consisting of each of SEQ ID NOs: 2, 3, 6, 7, 8, and 17;
the immunogenic fusion polypeptide consisting of each of SEQ ID NOs: 9-16;
the immunogenic fusion polypeptide consisting of each of SEQ ID NOs: 9, 10, 11, 14, 15, 16, and 18; and
the immunogenic fusion polypeptide consisting of each of SEQ ID NOs: 10, 11, 14, 15, 16, and 18.
17. The method of claim 16 , wherein the two or more immunogenic fusion polypeptides encoded by the one or more isolated nucleic acids are:
a polypeptide consisting of SEQ ID NOs: 1-8 and a polypeptide consisting of SEQ ID NOs: 9-16;
a polypeptide consisting of SEQ ID NOs: 1, 2, 3, 6, 7, 8, and 17, and a polypeptide consisting of SEQ ID NOs: 9, 10, 11, 14, 15, 16, and 18; or
a polypeptide consisting of SEQ ID NOs: 2, 3, 6, 7, 8, and 17, and a polypeptide consisting of SEQ ID NOs: 10, 11, 14, 15, 16, and 18.
18. The method of claim 15 , wherein the one or more isolated nucleic acids are administered to the subject simultaneously, substantially simultaneously, or sequentially.
19. The method of claim 15 , further comprising administering to the subject a therapeutically effective amount of an anti-viral agent.